Precision BioSciences, Inc. filings document regulatory disclosures for a clinical-stage gene editing company built around the ARCUS platform and in vivo therapeutic candidates. Recent Forms 8-K furnish operating results, financial-condition updates, business presentations, and Regulation FD materials covering PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, including IND-related and clinical-development disclosures.
The company’s proxy materials address board and stockholder meeting matters, executive compensation, equity plans, and governance proposals. Other filing categories cover material agreements, shareholder voting matters, capital-structure disclosures, inducement awards, and forward-looking risk language tied to clinical development, financing capacity, regulatory review, and public-company reporting.
Schedule 13G summary: Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach report beneficial ownership of 1,075,000 common shares of Precision BioSciences, representing 9.69% of the outstanding common stock. The filing shows the reporting persons hold sole voting and sole dispositive power over these shares and report no shared voting or dispositive power. Bleichroeder LP is identified as an investment adviser and is deemed to beneficially own the shares as adviser to various clients, while those clients retain the right to dividends and sale proceeds. The filing is submitted on Schedule 13G with exhibits for an agreement among reporting persons and subsidiary information.
Precision BioSciences (NASDAQ: DTIL) filed a Form 4 reporting that director Melinda Brown purchased 1,682 common shares on June 25 2025 at a weighted-average price of $4.14–$4.15. Following the transaction, Brown’s direct beneficial ownership increased to 20,565 shares.
No other non-derivative or derivative transactions were disclosed, and there were no sales. The filing contains a standard footnote explaining the weighted-average price range. No 10b5-1 trading plan box was checked.
Precision BioSciences (NASDAQ: DTIL) filed a Form 4 disclosing that director Kevin Buehler purchased 5,076 shares of common stock on 25 Jun 2025 at a weighted-average price of $4.16 per share (trade range: $4.16–$4.18). After the transaction, Buehler directly owns 28,137 shares, an increase of roughly 22% in his personal stake. The transaction was coded “P” for an open-market purchase, and the filing reports no sales or derivative security activity. No Rule 10b5-1 trading plan was indicated.